Skip to main content

Table 1 Participants will be eligible if they meet the following criteria

From: Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease

Inclusion criteria

a

Diagnosis of idiopathic Parkinson’s disease.

b

Modified Hoehn and Yahr stage 1 to 4 disease [21].

c

Have experienced a fall in the previous year.

d

Able to walk ≥10 m without aids or assistance.

e

18+ years of age

Exclusion criteria

a

Previous ChEi use during the 12 months prior to enrolment.

b

Hypersensitivity to rivastigmine

c

Dementia diagnosed according to Movement Disorder Society (MDS) criteria [22]

d

Inability to attend or comply with treatment or follow-up scheduling.

e

Non-English-speaking as the cognitive tests are performed in English.

f

Falling ≥4x per day.

g

Unwillingness to use an acceptable method of contraception for the duration of the trial if they are of childbearing potential.

h

Pregnant and/or breast feeding